Steven Kemps serves as Executive Vice President and Chief Legal Officer at S&P Global Inc., a leading provider of essential intelligence for financial markets. In this role, he oversees the company's global legal strategy, compliance programs, corporate governance, intellectual property, and risk management functions. Kemps plays a pivotal role in navigating complex regulatory environments, supporting major strategic initiatives, and ensuring ethical business practices across S&P Global's diverse operations, including ratings, indices, and market intelligence divisions. His leadership has been instrumental in the successful integration following the company's landmark merger with IHS Markit in 2022. Prior to joining S&P Global in April 2021, Kemps built an illustrious career in legal leadership within the pharmaceutical and healthcare sectors. He spent over seven years at Pfizer Inc., rising to Senior Vice President and Deputy General Counsel, where he led global mergers and acquisitions, corporate development, and antitrust matters. Notable achievements include orchestrating high-profile deals such as the acquisitions of Array BioPharma and Trillium Therapeutics, which bolstered Pfizer's oncology portfolio. Before Pfizer, Kemps was Vice President and Associate General Counsel at Johnson & Johnson from 2004 to 2013, advising on multibillion-dollar transactions and regulatory compliance. Earlier in his career, Kemps was a partner at Skadden, Arps, Slate, Meagher & Flom LLP, specializing in M&A and corporate finance for life sciences clients. A graduate of the University of Michigan Law School, he brings deep expertise in cross-border transactions, FDA regulations, and litigation strategy. Kemps is recognized for his strategic foresight and ability to drive value in dynamic industries, earning accolades such as being named one of the "Top 50 General Counsel" by Corporate Counsel.